PTX 104 - PharmEnable
Alternative Names: PTX-104 - PharmEnableLatest Information Update: 05 Aug 2024
Price :
$50 *
At a glance
- Originator PharmEnable
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 24 Jul 2024 PTX 104 - PharmEnable is available for licensing as of 24 Jul 2024. https://pharmenabletx.com/pipeline/ (PharmEnable pipeline, July 2024)
- 24 Jul 2024 Early research in Cancer in Isle of Man (unspecified route) prior to July 2024 (PharmEnable pipeline, July 2024)